Chicago、ILにおける血液がんの臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、血液がんに関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
被験者募集中第3相
- The University of Chicago ( Site 0020), Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 他1件
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
被験者募集中観察研究
- Swedish Covenant Hospital, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
被験者募集中観察研究健康なボランティア歓迎
- Tempus AI, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
被験者募集中
- Northwestern University Feinberg School of Medicine, Chicago
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- 他2件
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
被験者募集中第3相
- Northwestern University, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- University of Chicago, Chicago
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
被験者募集中
- University of Chicago Comprehensive Cancer Center, Chicago
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
被験者募集中第1相
- Northwestern University - Feinberg School of Medicine, Chicago
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
被験者募集中観察研究
- MPN Research Foundation, Chicago
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
被験者募集中第1相
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
他の都市における血液がんの試験
- Houston, TX46件の研究
- New York City, NY26件の研究
- Boston, MA25件の研究
- Washington, DC19件の研究
- Baltimore, MD18件の研究
- Seattle, WA18件の研究
- Los Angeles, CA17件の研究
- Durham, NC16件の研究
- Philadelphia, PA14件の研究
- Atlanta, GA13件の研究
- Nashville, TN13件の研究
- Edison, NJ13件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん58件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肥満症41件の研究
- 肺がん41件の研究
- 卵巣がん36件の研究
- 脳卒中34件の研究
- 大腸癌33件の研究
- 心不全31件の研究
- 過体重28件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。